Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Show more...
首席执行官
Ms. Caroline J. Loew Ph.D.
员工
116
国家
爱尔兰
上市
0 Comments
分享你的想法
FAQ
Mural Oncology 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 NASDAQ 交易所,Mural Oncology 的股票以代码 MURA V 进行交易。